Christine Zedelmayer Sells 23,804 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 23,804 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $1.34, for a total transaction of $31,897.36. Following the completion of the sale, the chief operating officer directly owned 103,344 shares in the company, valued at approximately $138,480.96. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The shares were sold at an average price of $1.31, for a total value of $15,589.00.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The stock was sold at an average price of $0.95, for a total transaction of $7,693.10.

Equillium Trading Down 4.7%

Shares of Equillium stock traded down $0.06 during trading hours on Monday, reaching $1.22. 469,524 shares of the company’s stock were exchanged, compared to its average volume of 2,628,076. Equillium, Inc. has a 52-week low of $0.27 and a 52-week high of $2.35. The company has a fifty day moving average of $1.17 and a 200-day moving average of $0.99. The firm has a market capitalization of $74.29 million, a price-to-earnings ratio of -1.97 and a beta of 1.93.

Equillium (NASDAQ:EQ) last released its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. On average, equities research analysts anticipate that Equillium, Inc. will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EQ has been the subject of a number of recent analyst reports. Wall Street Zen raised Equillium from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a report on Monday, December 8th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $1.00.

Institutional Investors Weigh In On Equillium

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC increased its holdings in Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after purchasing an additional 13,591 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Equillium during the third quarter worth $35,000. Persistent Asset Partners Ltd acquired a new stake in shares of Equillium in the third quarter valued at $99,000. Boothbay Fund Management LLC bought a new position in shares of Equillium in the third quarter valued at about $174,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Equillium during the 3rd quarter worth about $178,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.